Travere Therapeutics, Inc. 8-K

What Happened

• Travere Therapeutics, Inc. (NASDAQ: TVTX) filed an 8‑K on May 21, 2026 reporting that at its 2026 Annual Meeting of Stockholders the company’s stockholders approved an amendment to the 2018 Equity Incentive Plan to add 3,000,000 shares of common stock authorized for issuance.
• The definitive proxy for the Annual Meeting was filed with the SEC on April 6, 2026; the full text of the amended 2018 Equity Incentive Plan is attached to the 8‑K as Exhibit 99.1.
• The 8‑K is signed by Elizabeth E. Reed, Chief Legal Officer, General Counsel & Secretary. The filing also lists Item 5.02 (departure/election of directors or officers) but provides no substantive details in this report beyond the equity plan vote.

Key Details

• Vote outcome: Stockholders approved the amendment to the 2018 Equity Incentive Plan at the 2026 Annual Meeting.
• Increase: 3,000,000 additional shares of common stock authorized under the 2018 Plan.
• Related filings: Proxy statement filed April 6, 2026; amended plan filed as Exhibit 99.1 to the 8‑K (filed May 21, 2026).

Why It Matters

• Increasing the shares available under the equity incentive plan gives Travere flexibility to grant additional stock options, restricted stock, or other equity awards for employee and executive compensation, hiring and retention—common uses of such plans.
• For investors, the approval can lead to future equity-based compensation grants that may dilute existing shareholders over time; it also signals the company is preparing capacity to incentivize talent as it executes its business strategy.
• The filing provides the amended plan text (Exhibit 99.1) and references the proxy for more detail on the plan’s specific terms and limits.